| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47e6d64f3ca7f88ca5541672f0e21dca |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72 |
| filingDate |
2000-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fd526698185cd48eccdf815ce4ac5e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_499a2bddf3538c3f8f82afb51c6e0e0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af4acf2ec2c90c7a82bb32577382d7d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_396b0938ef7cb067291b01cd13f81ba0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca119d27aeb175b706c0533ec09c14f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61c7b2e08260b3c2b019771af301c0f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83e8590a96a52a9406d56cb9e0805a00 |
| publicationDate |
2000-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NO-20003246-L |
| titleOfInvention |
New pharmaceutical preparations of uridine triphosphate |
| abstract |
New pharmaceutical preparations of uridine 5'-triphosphate (UTP) for use in promoting increased mucociliary clearance of retained mucosal secretions in the respiratory tract, middle ear, or inner ear or the sinuses of humans. The new formulation (I) comprises UTP and aqueous solution having a therapeutic concentration between 5 and 45 mg / ml, a controlled tonicity in the range of 250 to 100 mOsM, a pH between 7.0 and 7.5, and is sterile. The pH-adjusted preparation can be stored for a long time in the refrigerated state with a storage resistance up to 30 months. Formulation (I) can be applied therapeutically either in a nebulized form or in a liquid form. The new formulation (II) comprises UTP in an aqueous solution having a therapeutic concentration approaching the solubility limit of UTP at ambient temperature or in a suspension exceeding the solubility of drug. This high concentration allows the administration of a therapeutic amount of UTP in very small volumes (50 to 100 µl) suitable for administration via portable handheld devices such as metered dose inhalers. Formulation (II) has prolonged storage resistance without the need for refrigeration upon assignment to the patient. |
| priorityDate |
1997-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |